ArticleNucleic acids research2026
exoRBase 3.0: an updated resource for extracellular RNAs from human biofluids.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- An integrated resource for systems-level analysis of aging hallmarks and associated genes.Biogerontology · 2026Article
- Integrative Bioinformatic Characterization of the HDAC6-Driven Cytoskeleton-Wnt Signaling Interface in Hepatocellular Carcinoma: Implications for Immune Modulation and Therapeutic Targeting.International journal of molecular sciences · 2026Article
- Extracellular vesicle-derived lncRNA-NEAT1 serves as potential biomarker for the early diagnosis of hepatocellular carcinoma.Translational cancer research · 2026Article
- Circulating RNA as a Functional Component of Liquid Biopsy in Cancer: Concepts, Classification, and Clinical Applications.International journal of molecular sciences · 2026Review
- 80 years of extracellular vesicles: from discovery to clinical translation.Extracellular vesicles and circulating nucleic acids · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Extracellular RNAs (exRNAs) in human biofluids have emerged as promising liquid biopsy biomarkers for noninvasive disease diagnosis and monitoring. Here, we present exoRBase 3.0 (http://www.exorbase.org), a significantly expanded database that systematically integrates and compares extracellular long RNAs (exLRs) derived from both extracellular vesicles and particles (EVPs) and cell-free RNA fractions. The database encompasses 19 927 messenger RNAs, 15 961 long non-coding RNAs, and 126 816 circular RNAs from 2913 samples across blood, urine, cerebrospinal fluid, and bile. A key advancement is the first large-scale comparative analysis platform that distinguishes between EVP-associated and cell-free exLRs, enabling identification of context-specific biomarkers and optimization of liquid biopsy strategies. Enhanced with interactive visualizations and expanded pathway analysis covering 12 981 gene sets, exoRBase 3.0 facilitates comprehensive comparative analysis of expression profiles, functional pathways, and tissue/cell origins across different sample types and disease states. This resource addresses the critical need for understanding how RNA biomarker performance varies between EVP and cell-free contexts, ultimately advancing precision medicine through improved liquid biopsy approaches for cancer diagnosis, disease monitoring, and therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.